Side-by-side · Research reference

ChonlutenvsDermorphin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED8/38 cited

BAnimal-StrongHUMAN-REVIEWED20/47 cited

Chonluten

Khavinson Bioregulator · Bronchial Mucosa

BronchialTarget tissue

In vitroEvidence tierAvolio 2022

THP-1Model systemAvolio 2022

Oral · Sublingual · Per Protocol

Dermorphin

Opioid Peptide · μ-Receptor Agonist · Research Only

~30×Morphine potency

μ-selectiveReceptor typeNegri 1992

D-Ala²Unique featureAmiche 1998

Research only · ICV / SC (animal models)

01Mechanism of Action

Parameter

Chonluten

Dermorphin

Primary target

Bronchial epithelial cells and respiratory mucosa tissue complexes

μ-opioid receptors (central and peripheral)Negri 1992 Steel 2014

Pathway

Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022

μ-receptor activation → G-protein coupling → adenylyl cyclase inhibition → neuronal hyperpolarization

Downstream effect

Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022

Potent analgesia, reduced nociceptive signaling, opioid-mediated CNS and peripheral effects

Feedback intact?

—

N/A — exogenous opioid agonist

Origin

Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology

Phyllomedusa sauvagei and P. bicolor frog skin — gene-encoded with natural D-amino acid incorporationAmiche 1998 Mignogna 1992

Antibody development

—

Site-directed antibodies produced for detection and purificationCucumel 1996

02Dosage Protocols

Parameter

Chonluten

Dermorphin

Typical protocol dose

10–20 mg / day

Russian bioregulator tradition dosing; not standardized in Western literature.

—

Frequency

Once or twice daily

—

Route

Oral (capsule) or sublingual

Sublingual claimed for enhanced bioavailability; not validated.

—

Evidence basis

In vitro mechanistic

Animal studies · In vitro assays

Duration

10–30 days per cycle

Traditional Khavinson protocol; cyclic administration common.

—

Clinical validation

None (PubMed indexed)

—

Legal status

—

Controlled substance in many jurisdictions · Research only

Not approved for human use.

Animal research (ICV)

—

Low nanomolar to picomolar range

Intracerebroventricular administration in rodent models.

Detection limit (doping)

—

5 pg/mL in equine plasma/urineSteel 2014

High-throughput LC-MS/MS screen developed for racing industry.

Duration of action

—

10–120 minutes (dose-dependent, intrathecal)

Human toxicity

—

Kambô ritual (P. bicolor skin) — violent emesis, vasodilation, fluid shifts, ADH dysregulationTran 2025

04Side Effects & Safety

Parameter

Chonluten

Dermorphin

Documented adverse events

No published safety data in PubMed-indexed literature

—

Theoretical risks

Peptide hypersensitivity, GI intolerance (uncharacterized)

—

Drug interactions

Unknown — no pharmacokinetic studies available

—

Pregnancy / lactation

No data — avoid

—

Opioid effects

—

Respiratory depression, sedation, euphoria, tolerance, dependence risk

CNS effects

—

Analgesia (high-affinity sites), catalepsy (low-affinity sites)Negri 1992

Kambô ritual toxicity

—

Violent emesis, vasodilation, profound fluid shifts, hyponatremia, ADH dysregulation, brain death (case report)Tran 2025

Peripheral effects

—

GI motility inhibition (ileum > vas deferens in vitro)Negri 1992

Receptor selectivity caveat

—

Two μ-receptor subtypes — differential behavioral effects (analgesia vs. catalepsy)Negri 1992

Proteolytic stability

—

Tyr³-Pro⁶ bond relatively unstable; endogenous enzymes may produce tetrapeptide fragmentsCucumel 1996

Absolute Contraindications

Chonluten

·Known hypersensitivity to peptide components

Dermorphin

·Human use — not approved by any regulatory authority
·Controlled substance status — possession illegal in many jurisdictions
·Known opioid hypersensitivity or respiratory compromise

Relative Contraindications

Chonluten

·Pregnancy and lactation (insufficient data)
·Active malignancy (theoretical bioregulator concern)

Dermorphin

·Any context outside approved animal research protocols
·CNS depressant co-administration

05Administration Protocol

Parameter

Chonluten

Dermorphin

1. Preparation

Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

Dermorphin is a controlled substance in many jurisdictions and is not approved for human use. Possession, synthesis, or distribution may be illegal. Use is restricted to licensed research settings under institutional review.

2. Oral route

Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

In rodent models, intracerebroventricular (ICV) or intrathecal injection is used at nanomolar to picomolar concentrations. Subcutaneous administration also documented. All protocols require IACUC approval.

3. Sublingual route

Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

High-throughput LC-MS/MS screens developed for anti-doping programs detect dermorphin and 17 related peptides in equine and human urine/plasma at limits as low as 5 pg/mL.Steel 2014

4. Timing

Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

Application of Phyllomedusa bicolor skin secretions to superficial burns. Not recommended — associated with severe toxicity including violent emesis, hyponatremia, and documented case of brain death.Tran 2025

5. Cycle protocol

10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

—